A citation-based method for searching scientific literature

Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, Allison Kemner, Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D Wilner, Koichi Goto. J Clin Oncol 2018
Times Cited: 129



Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild, Federico Cappuzzo, Benjamin Besse, Luc Thiberville, Damien Rouvière, Rafal Dziadziuszko, Egbert F Smit, Jurgen Wolf, Christian Spirig, Nicolas Pecuchet, Frauke Leenders, Johannes M Heuckmann, Joachim Diebold, Julie D Milia, Roman K Thomas, Oliver Gautschi. J Clin Oncol 2015
Times Cited: 232




List of shared articles



Times cited

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
22



Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
3

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
5

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
2

Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
0

ROS1 Targeted Therapies: Current Status.
Christine M Azelby, Mandy R Sakamoto, Daniel W Bowles. Curr Oncol Rep 2021
2

Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC.
Robert C Doebele, Laura Perez, Huong Trinh, Michael Martinec, Reynaldo Martina, Todd Riehl, Matthew G Krebs, Neal J Meropol, William B Wong, Gracy Crane. J Comp Eff Res 2021
0

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Jaclyn M Beca, Shaun Walsh, Kaiwan Raza, Stacey Hubay, Andrew Robinson, Elena Mow, James Keech, Kelvin K W Chan. BMC Cancer 2021
0

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
0

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
David Waterhouse, Laura Iadeluca, Sneha Sura, Keith Wilner, Birol Emir, Stan Krulewicz, Janet Espirito, Lauren Bartolome. Target Oncol 2021
0

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
P Garrido, E Conde, J de Castro, J J Gómez-Román, E Felip, L Pijuan, D Isla, J Sanz, L Paz-Ares, F López-Ríos. Clin Transl Oncol 2020
24

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Subba R Digumarthy, Dexter P Mendoza, Jessica J Lin, Tianqi Chen, Marguerite M Rooney, Emily Chin, Lecia V Sequist, Jochen K Lennerz, Justin F Gainor, Alice T Shaw. Clin Lung Cancer 2020
12

Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
F Passiglia, S Pilotto, F Facchinetti, L Bertolaccini, M Del Re, R Ferrara, T Franchina, U Malapelle, J Menis, A Passaro,[...]. Crit Rev Oncol Hematol 2020
24

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Haiyan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying,[...]. Cancer Med 2020
6

ROS1-rearranged Non-small Cell Lung Cancer.
Nicholas P Giustini, Lyudmila Bazhenova. Thorac Surg Clin 2020
2

A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Juming Li, Lingxiang Liu, Qi Zhang, Yumin Huang, Yihong Zhang, Xiaoyan Gan, Siqin Liu, Zhen Yue, Yongzhong Wei. Medicine (Baltimore) 2020
1

[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Fernando López-Ríos, Luis Paz-Ares, Julián Sanz, Dolores Isla, Lara Pijuan, Enriqueta Felip, José Javier Gómez-Román, Javier de Castro, Esther Conde, Pilar Garrido. Rev Esp Patol 2020
1

Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.
Huy Gia Vuong, Thu Quynh Nguyen, Hoang Cong Nguyen, Phuoc Truong Nguyen, An Thi Nhat Ho, Lewis Hassell. Target Oncol 2020
5

Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Yun Shu, Hui Li, Hongjuan Shang, Jun Chen, Xiaoxing Su, Wei Le, Yan Lei, Liming Tao, Cailiang Zou, Wendy Wu. Onco Targets Ther 2020
1

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
10

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
3

How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease.
Lorenza Landi, Federico Cappuzzo. Transl Lung Cancer Res 2020
0

Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer.
Qing Zhang, Chunyan Wu, Wei Ding, Zhihong Zhang, Xueshan Qiu, Dianbin Mu, Haiqing Zhang, Yanfeng Xi, Jianhua Zhou, Liheng Ma,[...]. Thorac Cancer 2019
11


ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report.
Hiroyuki Ogawa, Yugo Tanaka, Motoko Tachihara, Keiichiro Uehara, Nahoko Shimizu, Takefumi Doi, Daisuke Hokka, Yoshimasa Maniwa. Oncol Lett 2019
2


Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer.
You-Cai Zhu, Xin-Gen Zhang, Xue-Ping Lin, Wen-Xian Wang, Xiao-Feng Li, Li-Xin Wu, Hua-Fei Chen, Chun-Wei Xu, Kai-Qi Du. Oncol Lett 2019
6


Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.
David F Heigener, Keith M Kerr, Gavin M Laing, Tony S K Mok, Fedor V Moiseyenko, Martin Reck. Clin Cancer Res 2019
4

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib.
Yueming He, Wang Sheng, Weiguo Hu, Jing Lin, Junjun Liu, Bing Yu, Xinru Mao, Lu Zhang, Jin Huang, Guangsuo Wang. Oncol Res 2019
11

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
Chang Liu, Hui Yu, Jianhua Chang, Haiquan Chen, Yuan Li, Weixin Zhao, Kuaile Zhao, Zhengfei Zhu, Si Sun, Min Fan,[...]. Target Oncol 2019
9

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff,[...]. J Thorac Oncol 2019
34